Angiogenesis Inhibitors in NSCLC
Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with a...
Main Authors: | Anna Manzo, Agnese Montanino, Guido Carillio, Raffaele Costanzo, Claudia Sandomenico, Nicola Normanno, Maria Carmela Piccirillo, Gennaro Daniele, Francesco Perrone, Gaetano Rocco, Alessandro Morabito |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-09-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/18/10/2021 |
Similar Items
-
Focus on Nintedanib in NSCLC and other tumors
by: Anna Manzo, et al.
Published: (2016-12-01) -
Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?
by: Alessandro Morabito
Published: (2018-02-01) -
Selection of the anti-angiogenesis therapy for the first-line chemotherapy in advanced ovarian cancer
by: S V Khokhlova
Published: (2014-03-01) -
Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence
by: De Luca E, et al.
Published: (2020-05-01) -
Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer
by: Cooper MR, et al.
Published: (2016-04-01)